US Patent 11285210 Buffer formulations for enhanced antibody stability
Patent 11285210 was granted and assigned to Outlook Therapeutics, Inc. on March, 2022 by the United States Patent and Trademark Office.
All edits
Edits on 16 Oct, 2023
Golden AI
Edits made to:
Infobox (+3 properties)
Infobox
Patent Inventor Names
Hiten Gutka0
Jessica Cheung0
Maria Taddei0
Edits on 20 May, 2023
Golden AI
Edits made to:
Infobox (-1 properties)
Infobox
Official Website
Edits on 30 Mar, 2023
Golden AI
Infobox
Edits on 27 Mar, 2023
Golden AI
Infobox
Edits on 23 Mar, 2023
Golden AI
Infobox
Is a
Patent Applicant
Current Assignee
0
Patent Jurisdiction
Patent Number
112852100
Date of Patent
March 29, 2022
0Patent Application Number
160729910
Date Filed
February 1, 2017
0Official Website
Patent Citations
Patent Primary Examiner
Edits on 27 Sep, 2022
Golden AI
Infobox
Edits on 6 Jun, 2022
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Website URL
Edits on 30 Mar, 2022
Golden AI
Edits made to:
Infobox (+11 properties)
Article (+385 characters)
US Patent 11285210 Buffer formulations for enhanced antibody stability
Article
The disclosure provides buffered formulations of adalimumab. The formulations comprise a buffer comprising an acetate salt, sorbitol, histidine and/or a histidine salt and optionally arginie and/or an arginine salt, and polysorbate 80. The formulations have an acidic pH, and enhance the thermal, conformational and colloidal stability of antibodies, including the adalimumab antibody.
Infobox
Is a
Patent applicant
Current assignee
Patent jurisdiction
Patent number
11285210
Date of patent
March 29, 2022
Patent application number
16072991
Date Filed
February 1, 2017
Patent citations
Patent primary examiner
Find more entities like US Patent 11285210 Buffer formulations for enhanced antibody stability
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
